Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Summary

The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

Eligibility

Inclusion Criteria:

1. Male or female between the ages of 18 and 100 years.
2. Elevated NT-proBNP or BNP levels on admission.
3. Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III, or IV symptoms.

Exclusion Criteria:

1. Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance of an SGLT2 inhibitor.
2. Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization.
3. Pregnant or breast feeding female patients.

Conditions3

Interventions1

Related trials

• CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL — 4th Military Clinical Hospital with Polyclinic, Poland
• Dapagliflozin in Depression — Tanta University
• Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure — Fundación para la Investigación del Hospital Clínico de Valencia
• Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome — Future University in Egypt
• Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes — University of Sao Paulo
• SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes — The George Institute
• Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer — Washington University School of Medicine
• Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) — Washington University School of Medicine

Browse More Trials